GlassScriptPhysician profile
Ryan Robert Johnston
NPI 1881777373
$4,066.06
in general payments reported to CMS, 2019-2025
33 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.10 · 2022: $904 · 2023: $831 · 2024: $1,004 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.85 |
| Education | $177.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.40 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $384.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $367.96 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $332.88 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $325.46 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $302.18 | 2022-2025 | |
| Astellas Pharma US INC | $279.72 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $185.89 | 2023-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $138.17 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $137.21 | 2022-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $129.56 | 2022 | |
| Amgen INC. | $120.42 | 2021-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $119.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $82.58 | 2024-2025 | Sunosi, Auvelity |
| Alexion Pharmaceuticals, INC. | $78.93 | 2022-2024 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $77.40 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $62.49 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.25 | 2021-2022 | |
| Bausch Health US, LLC | $52.60 | 2022 | |
| Medtronic, INC. | $45.28 | 2024-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Averitas Pharma INC. | $42.50 | 2024 | Qutenza |
| Edwards Lifesciences Corporation | $42.31 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $40.86 | 2022 | |
| Vanda Pharmaceuticals INC. | $39.61 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.16 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.59 | 2022-2023 | Xifaxan |
| Grifols USA, LLC | $21.29 | 2023 | Prolastin-C Liquid |
| Supernus Pharmaceuticals, INC. | $19.08 | 2024 | Qelbree |
| Phathom Pharmaceuticals, INC. | $18.51 | 2025 | Voquezna |
| Seqirus USA INC | $17.60 | 2024 | Fluad, Flucelvax |
| Acella Pharmaceuticals, LLC | $16.78 | 2024 | NP Thyroid 60 |
| Boston Scientific Corporation | $15.94 | 2025 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $13.91 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.